Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy.
Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy.
复制标题
DOI：
10.1186/s12882-022-02814-7
复制
发表时间：
2022-05-10
期刊：
影响因子：
2.3
通讯作者：
Yang, Fan
中科院分区：
文献类型：
--
作者：
Le, Wei-Bo;Shi, Jin-Song;Gong, Si-Wen;Yang, Fan
雷公藤多苷制剂(雷公藤多苷，雷公藤多甙，雷公藤多苷)已广泛用于治疗中国的IgA肾病。然而，新一代雷公藤制剂苦心仙胶囊治疗IgA肾病的有效性和安全性仍不清楚。在这里，我们回顾了我们用坤仙治疗连续55例IgAN患者的经验。我们将完全缓解定义为蛋白尿+lt； 0.5 g/24 h，部分缓解定义为蛋白尿+lt； 1 g/24 h，两组均较基线水平尿蛋白减少50%。昆仙治疗后首次随访(5.7 周，IQR4.7-7.9)，除2例(96%)患者外，其余患者的蛋白尿均有减少。总的中位数蛋白尿从基线的2.23 g/d降至第一次随访时的0.94 g/d(P <； 0.001)。用药后中位随访28 周，完全缓解25例(45.5%)，完全/部分缓解34例(61.8%)。停用坤显治疗的12例患者中，中位尿蛋白从0.97 g/24 h升至2.74 g/24 h，中位数为10.9 周(P = 0.004)。多变量COX模型显示，女性、改用上一代雷公藤制剂、较低的初始坤仙剂量和基线较高的蛋白尿是蛋白尿缓解的独立相关因素。20例绝经前女性中，12例月经过少或月经不调，10例闭经。坤贤治疗IgA肾病安全有效。育龄妇女在接受雷公藤制剂治疗后被告知卵巢衰竭的风险。
Tripterygium Wilfordii Hook F (TwHF) preparation has been widely used in the treatments of IgA nephropathy (IgAN) in China. However, the effectiveness and safety of the new generation of TwHF preparation, KuxXian capsule, on the treatment of IgAN remains unknown. Here, we retrospectively describe our experience treating 55 consecutive IgAN patients with KunXian. We defined complete remission as proteinuria < 0.5 g/24 h and partial remission as proteinuria < 1 g/24 h, each also having > 50% reduction in proteinuria from baseline. At first follow-up after KunXian treatment (5.7 weeks, IQR 4.7–7.9), all but two patients (96%) showed a reduction in proteinuria. The overall median proteinuria decreased from 2.23 g/day at baseline to 0.94 g/day (P < 0.001) at the first follow-up. During a median follow-up of 28 weeks after KunXian administration, 25(45.5%) patients achieved complete remission, 34 (61.8%) patients achieved complete/partial remission. Of the 12 patients discontinued KunXian treatment during the follow-up, the median proteinuria was increased from 0.97 g/24 h to 2.74 g/24 h after a median of 10.9 weeks (P = 0.004). Multivariable Cox models showed that female, treatment switching from previous generation of TwHF preparation, lower initial KunXian dosage, and higher proteinuria at baseline were independently associated proteinuria remission. Of the 20 pre-menopausal females, 12 of them developed oligomenorrhea or menstrual irregularity and ten of them developed amenorrhea. KunXian is effectiveness and safety for the treatment of IgA nephropathy. Woman of childbearing age to be informed of the risk of ovarian failure after being treated with TwHF preparations.
登录
查看更多内容
影响因子：
6.1
作者：
Gao, Qing;Shen, Wenwen;Liu, Zhihong
通讯作者：
Liu, Zhihong
影响因子：
7.5
作者：
Jing, Xiaoping;Cheng, Weiwei;He, Li
通讯作者：
He, Li
影响因子：
19.6
作者：
Chen, Zhao-Hong;Qin, Wei-Song;Liu, Zhi-Hong
通讯作者：
Liu, Zhi-Hong
影响因子：
2
作者：
Wang, Zhen;Yu, Chao;Chen, Xin
通讯作者：
Chen, Xin
雷公藤红 (Tripterygium wilfordii Hook F) 与甲氨蝶呤治疗活动性类风湿关节炎 (TRIFRA) 的比较：一项随机对照临床试验。
影响因子：
27.4
作者：
Lv, Qian-wen;Zhang, Wen;Zhang, Xuan
通讯作者：
Zhang, Xuan